Olink Proteomics announces the availability of the most comprehensive, high-multiplex protein biomarker panel for mouse studies

Press Releases   •   Dec 14, 2017 07:30 EST

Olink Proteomics today announced the launch of Olink® MOUSE EXPLORATORY, offering 92 high-quality assays to measure mouse proteins. The panel is based on the same, well-established Proximity Extension Assay (PEA) technology behind Olink’s portfolio of high-multiplex panels for human protein biomarker discovery, and has been developed to the same high standards of validation and quality control.

Olink Proteomics announces a new oncology-focused biomarker panel that expands its protein library to over 1100 high-quality assays

Press Releases   •   Dec 13, 2018 07:30 EST

Olink Proteomics today announced the launch of Olink® ONCOLOGY III, a new oncology-focused biomarker panel that complements and expands on Olink's growing portfolio of thoroughly validated assays, extending the power of the Olink platform for discovery-scale applications to 1164 different human protein biomarkers.

Protein biomarkers making an impact in clinical trials for Atopic Dermatitis.

News   •   Oct 31, 2018 08:58 EDT

DS Biopharma have announced in a press release that oral treatment with the immunomodulating, bioactive lipid, DS107 reversed the molecular signature of Atopic Dermatitis (AD) patients in a phase 2b clinical trial. Protein data generated using Olink’s biomarker panels provided evidence of the favorable effect of the compound, based on the reversal of the AD molecular signature. For more details, please read the full press release. If you have any questions about this exciting development, please contact DS Biopharma directly.

DS Biopharma have announced in a press release that oral treatment with the immunomodulating, bioactive lipid, DS107 reversed the molecular signature of Atopic Dermatitis (AD) patients in a phase 2b clinical trial.

Read more »

Olink Proteomics announces a new biomarker panel that expands its protein library to over 1000 high-quality assays

Press Releases   •   Aug 31, 2018 08:00 EDT

Olink Proteomics today announced the launch of Olink® NEURO EXPLORATORY, a new biomarker panel that complements and expands on Olink's growing portfolio of high quality protein assays, extending the power of the Olink platform for discovery-scale application to 1072 different protein biomarkers. This will enable scientists to cast an even broader net in their protein biomarker screening studies.

New booklet from Science & Olink

News   •   Oct 18, 2017 06:49 EDT

Olink present a new sponsored Supplement produced by the Science/AAAS Custom Publishing Office that will enable the scientific community to learn more about biomarker discovery strategies to advance precision medicine.

Olink Proteomics announces the availability of three additional biomarker panels focused on key biological processes with broad clinical relevance

Press Releases   •   Feb 16, 2017 08:00 EST

Olink Proteomics today announced the launch of three new precision proteomics panels, further expanding its rapidly growing library of high quality human protein biomarker assays to almost 1000. The focus areas for these three new panels are Cardiometabolic, Cell Regulation and Development.

Olink Proteomics announces the availability of three new biomarker panels to further explore the complexities of the human proteome

Press Releases   •   Nov 29, 2016 08:32 EST

Olink Proteomics today announced the launch of three new precision proteomics panels, significantly expanding its library of high quality human protein biomarker assays, from 460 to over 700. This series of new panels is designed to enable scientists to extend their discovery capabilities for studying the plasma proteome by casting a broader net.

Olink Proteomics announces the availability of the broadest and most complete protein biomarker panel for immuno-oncology

Press Releases   •   Sep 21, 2016 10:43 EDT

Olink Proteomics today announced that Proseek® Multiplex Immuno-Onc I, the broadest protein biomarker panel targeting critical biological process related to immunotherapy, is now available for immediate delivery. Developed to meet a clearly expressed need from customers, the panel is designed to help companies, scientists and clinicians working with immunotherapy-based approaches to treat cancer.

Open for business in the USA: Olink Proteomics unveils a new office and analysis service laboratory in the Boston area.

Press Releases   •   May 31, 2016 06:29 EDT

Olink Proteomics is delighted to announce the opening of new office and laboratory facilities in Watertown, Massachusetts. This heralds the establishment of the company’s first major regional organization outside of Sweden, and will support the rapidly growing business in the United States.

Focusing for success: A new Olink company organization to meet our future ambitions

Press Releases   •   Apr 12, 2016 08:00 EDT

Uppsala, Sweden, April 12, 2016 - Olink AB has gone through a formal reorganization, and as of April 1, 2016 is operating as two separate companies, each with its own distinct focus area.

Olink Proteomics will continue to expand and develop the Proseek® Multiplex product line for human protein biomarker discovery. With all the company’s resources fully dedicated towards this flagship precision proteomics platform, Olink Proteomics aims to provide its customers with an ever-expanding range of high quality multiplex immunoassays for biomarker discovery, and support the future development of diagnostic tools based on clinically relevant protein signatures. This singular focus on Proseek demonstrates Olink Proteomics’ absolute commitment to provide the best possible solutions for our current and future customers in the protein biomarker field.

The CEO for Olink Proteomics AB is Lotta Falck

Email:lotta.falck@olink.com

Web: www.olinkproteomics.com

Phone +46 702 71 01 07

Olink Bioscience will focus on developing and commercializing the many additional technologies held within Olink's extensive and growing, diverse IP portfolio. With a strong R&D team dedicated to developing these new technologies in collaboration with scientists at Uppsala University, Olink Bioscience aims to continue its successful work providing access to new and innovative molecular tools for life science researchers and for molecular diagnostics.

The CEO for Olink Bioscience is Peter Åsberg

Email:peter.asberg@olinkbioscience.com

Web:www.olinkbioscience.com

Phone +46 709 49 17 21

This reorganization of Olink’s wider business will enable each of the two new companies to focus 100% on its primary objective, with fully dedicated resources and a clear sense of direction.

“The company division reflects both the desire to best serve the needs and expectations of customers in our rapidly growing Proseek business, and the deep seated commitment to develop exciting new molecular tools for the wider scientific community. Both of these can now be pursued with total focus and without compromise” say Andrea Ballagi, VP Sales & Marketing at Olink Proteomics and Peter Åsberg, CEO at Olink Bioscience.

If you have questions about this reorganization, please contact Magnus Eriksson, Chief Financial Officer, Olink Proteomics:

E-mail: magnus.eriksson@olink.com

Phone +46 18 444 39 70

Product and technology information
Proseek Multiplex is based on the proprietary Proximity Extension Assay (PEA) technology developed by Olink. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules, which upon target binding give rise to new DNA amplicons, each ID-barcoding their respective target protein. Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR. This dual recognition, DNA-coupled method provides exceptional readout specificity, enabling Proseek Multiplex to achieve a combination of high multiplexing and excellent data quality that cannot be matched using standard immunoassay techniques. An animation illustrating how the technology works and what it is used for can be viewed on our YouTube channel.

For research use only. Not for use in diagnostic procedures.

Olink Proteomics and Olink Bioscience are headquartered in Uppsala, Sweden.

For more information, please visit www.olink.com.

Olink and Proseek are registered trademarks of Olink AB.

Uppsala, Sweden, April 12, 2016 - Olink AB has gone through a formal reorganization, and as of April 1, 2016 is operating as two separate companies, each with its own distinct focus area.

Read more »

Images & Videos 1 image, 2 videos

Contacts 2 contacts

  • Press Contact
  • Marketing Communications Manager
  • Marketing Communications
  • gastrygn.fcvraylnkhxlipan@zsolheinptk.bfcovcmip
  • +46722518330
  • +46722518330

About Olink Proteomics

Swedish company Olink Proteomics provides innovative solutions for targeted human protein biomarker discovery.

Through our dedication to innovation, quality, rigor and transparency, Swedish company Olink Proteomics provides outstanding products and services for human protein biomarker research. We help scientists get answers quickly and confidently through robust, multiplex biomarker analysis. Olink® panels enable rapid, high-throughput analysis, with exceptional data quality and minimal sample consumption. Using just 1 µl of sample, 92 biomarkers are assayed simultaneously, with up to 96 samples run per panel. Our Proximity Extension Assay (PEA) technology enables this high level of multiplexing, as this dual recognition, DNA-coupled method provides exceptional readout specificity. Disease area-focused panels have both validated and exploratory biomarkers, selected in collaboration with leading experts, and our rigorous assay validation data is freely available. Choosing either ready-to-use kits or our Olink Analysis Service, customers get high quality data and rapid high-throughput analysis that makes the most effective use of their precious samples.

Olink Proteomics is headquartered in Uppsala, Sweden and also has an office and service laboratory for its US regional organization, based in Watertown MA.

Address

  • Olink Proteomics
  • 201 Dexter Avenue
  • 02472 Watertown, MA
  • United States
  • Our homepage